Amgen misses EPS estimate

AMGN missed its fourth quarter and full year EPS estimates by a penny, largely due to increased spending in the fourth quarter to support two product launches. AMGN reported fourth quarter and

Read the full 328 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE